Results 101 to 110 of about 14,385 (213)

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

open access: yesBritish Journal of Haematology, Volume 209, Issue 4, Page 1450-1468, October 2026.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo   +3 more
wiley   +1 more source

CD123-targeting immunotherapeutic approaches in acute myeloid leukaemia

open access: yes
Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies.
Dreyzin, Alexandra   +2 more
core   +1 more source

Example of the gating strategy for monocytes- LiveDead Aqua (LDA)-/CD1c-/CD19-/CD36+/CD123-/CD303-.

open access: yes, 2013
Example of the gating strategy for monocytes- LiveDead Aqua (LDA)-/CD1c-/CD19-/CD36+/CD123-/CD303-.
Daniel H. Libraty (110206)   +6 more
core   +1 more source

Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia

open access: yes, 2019
Monoclonal antibodies are being considered as biopharmaceuticals for the in vivo targeting of acute myeloid leukemia. Here we describe the generation and characterization of a fully-human monoclonal antibody specific to CD123, a surface marker which is ...
Manz, Markus G   +6 more
core   +2 more sources

The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes

open access: yesHaematologica, 2004
BACKGROUND AND OBJECTIVES: CD123 is an antibody that identifies the a chain of the human interleukin-3 receptor and is expressed in a variety of normal hematopoietic cells, acute leukemia and hairy cell leukemia (HCL).
I Del Giudice   +9 more
doaj  

Abstract 597: Bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecules for redirected T-cell cytotoxicity in hematological malignancies

open access: yes, 2017
Introduction: CD123 is a component of the IL-3 receptor expressed in several hematological malignancies including AML, ALL, HCL, and MDS. CD123 is a compelling target in AML due to its overexpression on AML blasts as well as leukemic stem cells, which ...
Rebecca Gottschalk   +22 more
core   +1 more source

CD123 monoclonal antibody in myelodysplastic syndrome

open access: yesHematology/Oncology and Stem Cell Therapy, 2011
De Salvo, Luigi   +11 more
openaire   +2 more sources

Acute Myeloid Leukemia With Florid Plasmacytoid Dendritic Cell Expansion and Aberrant Expression of CD19

open access: yes
International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 919-920, October 2026.
Afshin Shameli, Russell K. Dorer
wiley   +1 more source

Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells

open access: yes
International audienceAbstract Chimeric antigen receptor (CAR) T cells express an extracellular domain consisting of a single-chain fragment variable (scFv) targeting a surface tumor-associated antigen. scFv selection should involve safety profiling with
Anna, François   +23 more
core   +1 more source

Home - About - Disclaimer - Privacy